A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia
Details
Serval ID
serval:BIB_6226658075C7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia
Journal
American Journal of Respiratory and Critical Care Medicine
ISSN
1073-449X (Print)
Publication state
Published
Issued date
01/2006
Volume
173
Number
1
Pages
91-7
Notes
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Jan 1
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Jan 1
Abstract
RATIONALE: Iseganan, an antimicrobial peptide, is active against aerobic and anaerobic gram-positive and gram-negative bacteria as well as fungi and yeasts. The drug has shown little resistance in vitro and to be safe and well tolerated in 800 patients with cancer treated for up to 6 wk. OBJECTIVES: To determine the efficacy of iseganan for the prevention of ventilator-associated pneumonia (VAP). METHODS: Mechanically ventilated patients in the United States and Europe were randomized to oral topical iseganan or placebo (1:1) and treated six times per day while intubated for up to 14 d. Patients were eligible if randomized within 24 h of intubation and estimated to survive and remain mechanically ventilated for 48 h or more. The primary efficacy endpoint of the study was VAP measured among survivors at Day 14. MEASUREMENTS AND MAIN RESULTS: A total of 709 patients were randomized and received at least one dose of study drug. The two groups were comparable at baseline except iseganan-treated patients were, on average, 3 yr older. The rate of VAP among survivors at Day 14 was 16% (45/282) in patients treated with iseganan and 20% (57/284) in those treated with placebo (p = 0.145). Mortality at Day 14 was 22.1% (80/362) in the iseganan group compared with 18.2% (63/347) in the placebo group (p = 0.206). No pattern of excess adverse events in the iseganan group compared with placebo was observed. CONCLUSIONS: Iseganan is not effective in improving outcome in patients on prolonged mechanical ventilation.
Keywords
Administration, Oral
Administration, Topical
Adult
Aged
Anti-Infective Agents/*administration & dosage/therapeutic use
Double-Blind Method
Humans
Male
Middle Aged
Peptides/*administration & dosage/therapeutic use
Pneumonia/etiology/*prevention & control
Respiration, Artificial/*adverse effects
Treatment Outcome
Pubmed
Web of science
Create date
24/01/2008 17:57
Last modification date
20/08/2019 15:19